TWI794232B - 激酶抑制劑及其用途 - Google Patents

激酶抑制劑及其用途 Download PDF

Info

Publication number
TWI794232B
TWI794232B TW107116834A TW107116834A TWI794232B TW I794232 B TWI794232 B TW I794232B TW 107116834 A TW107116834 A TW 107116834A TW 107116834 A TW107116834 A TW 107116834A TW I794232 B TWI794232 B TW I794232B
Authority
TW
Taiwan
Prior art keywords
membered
alkyl
cycloalkyl
pharmaceutically acceptable
haloalkyl
Prior art date
Application number
TW107116834A
Other languages
English (en)
Chinese (zh)
Other versions
TW201900618A (zh
Inventor
後補 後補
安東尼 A 艾斯特達
健文 馮
布萊恩 福克斯
辛希亞 瑪利亞 法蘭西尼
克里斯托福 R H 海爾
科林 菲力普 萊斯利
邁可森 歐希波夫
伊蓮娜 瑟拉
札克利 K 史溫利
亞倫 托圖姆克拉
Original Assignee
美商戴納立製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商戴納立製藥公司 filed Critical 美商戴納立製藥公司
Publication of TW201900618A publication Critical patent/TW201900618A/zh
Application granted granted Critical
Publication of TWI794232B publication Critical patent/TWI794232B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TW107116834A 2017-05-17 2018-05-17 激酶抑制劑及其用途 TWI794232B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762507698P 2017-05-17 2017-05-17
US62/507,698 2017-05-17
US201862664895P 2018-04-30 2018-04-30
US62/664,895 2018-04-30

Publications (2)

Publication Number Publication Date
TW201900618A TW201900618A (zh) 2019-01-01
TWI794232B true TWI794232B (zh) 2023-03-01

Family

ID=64274744

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107116834A TWI794232B (zh) 2017-05-17 2018-05-17 激酶抑制劑及其用途

Country Status (21)

Country Link
US (3) US11203600B2 (enExample)
EP (1) EP3624797A4 (enExample)
JP (2) JP7064512B2 (enExample)
KR (1) KR102638151B1 (enExample)
CN (3) CN110913858B (enExample)
AU (1) AU2018269743B2 (enExample)
BR (1) BR112019023918A2 (enExample)
CA (1) CA3063934A1 (enExample)
CL (1) CL2019003263A1 (enExample)
CO (1) CO2019012957A2 (enExample)
CR (1) CR20190566A (enExample)
DO (1) DOP2019000290A (enExample)
EC (1) ECSP19089214A (enExample)
IL (1) IL270648B2 (enExample)
MX (2) MX2019013645A (enExample)
MY (1) MY200328A (enExample)
PE (2) PE20241932A1 (enExample)
PH (1) PH12019550235A1 (enExample)
SG (1) SG10201913927VA (enExample)
TW (1) TWI794232B (enExample)
WO (1) WO2018213632A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220072019A1 (en) * 2018-10-19 2022-03-10 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
IL291665B2 (en) * 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
TWI873290B (zh) 2020-02-13 2025-02-21 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
KR200493347Y1 (ko) 2020-07-06 2021-03-17 박혜진 휴대가 용이한 마스크
BR112023016539A2 (pt) * 2021-02-19 2023-11-14 Kalvista Pharmaceuticals Ltd Inibidores do fator xiia
WO2022231928A1 (en) * 2021-04-27 2022-11-03 Merck Sharp & Dohme Llc Ripk1 inhibitors and methods of use
EP4329765A4 (en) * 2021-04-27 2025-06-11 Merck Sharp & Dohme LLC Phenylazepines as RIPK1 inhibitors and methods of using them
JP2024544533A (ja) 2021-11-11 2024-12-03 ジェンザイム・コーポレーション Ｒｉｐｋ１阻害剤としてのイソオキサゾリジン及びその使用
TW202417453A (zh) * 2022-07-25 2024-05-01 美商戴納立製藥公司 ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶並［３，４－ｆ］［１，４］氧氮呯－９－甲腈的固體形式
US20240100065A1 (en) * 2022-08-23 2024-03-28 Genzyme Corporation Methods for treating receptor-interacting protein kinase 1-mediated diseases
TW202444357A (zh) * 2023-01-23 2024-11-16 美商健臻公司 ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶并［３，４－ｆ］［１，４］氧氮呯－９－甲腈之藥品調配物
TW202515552A (zh) * 2023-06-27 2025-04-16 美商健臻公司 製備4-(3,3-二氟-2,2-二甲基-丙醯基)-3,5-二氫-2h-吡啶并[3,4-f][1,4]氧雜氮呯-9-腈之方法
CN120365288A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物
CN120365287A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140100216A1 (en) * 2011-05-20 2014-04-10 Nikolay Filippovich Savchuk Stimulators of incretin hormones secretion, method for preparation and use thereof
US20160222028A1 (en) * 2015-02-02 2016-08-04 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
EP1329450A4 (en) 2000-09-27 2005-08-31 Ajinomoto Kk BENZODIAZEPINE DERIVATIVE
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
TWI648273B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
CN104059068B (zh) 2013-03-20 2017-02-08 中国科学院上海药物研究所 β‑氨基羰基类化合物、其制备方法、药物组合物及其用途
TWI730959B (zh) * 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
EP3307739B1 (en) * 2015-06-15 2020-10-07 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140100216A1 (en) * 2011-05-20 2014-04-10 Nikolay Filippovich Savchuk Stimulators of incretin hormones secretion, method for preparation and use thereof
US20160222028A1 (en) * 2015-02-02 2016-08-04 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors

Also Published As

Publication number Publication date
AU2018269743B2 (en) 2024-01-11
US11203600B2 (en) 2021-12-21
BR112019023918A2 (pt) 2020-06-02
US20220041620A1 (en) 2022-02-10
CN119264073A (zh) 2025-01-07
CO2019012957A2 (es) 2020-05-29
TW201900618A (zh) 2019-01-01
JP7241825B2 (ja) 2023-03-17
JP7064512B2 (ja) 2022-05-10
MY200328A (en) 2023-12-20
KR102638151B1 (ko) 2024-02-16
EP3624797A1 (en) 2020-03-25
MX2019013645A (es) 2020-09-17
WO2018213632A1 (en) 2018-11-22
DOP2019000290A (es) 2020-03-15
ECSP19089214A (es) 2020-05-29
IL270648A (enExample) 2020-01-30
CN119285572A (zh) 2025-01-10
JP2020520924A (ja) 2020-07-16
US20250011338A1 (en) 2025-01-09
PE20200729A1 (es) 2020-07-23
IL270648B2 (en) 2024-03-01
CN110913858B (zh) 2024-09-24
CA3063934A1 (en) 2018-11-22
CR20190566A (es) 2020-06-14
EP3624797A4 (en) 2021-07-21
PE20241932A1 (es) 2024-09-24
US12129263B2 (en) 2024-10-29
JP2021193116A (ja) 2021-12-23
CN110913858A (zh) 2020-03-24
SG10201913927VA (en) 2020-03-30
IL270648B1 (en) 2023-11-01
PH12019550235A1 (en) 2020-07-20
KR20200006125A (ko) 2020-01-17
AU2018269743A1 (en) 2020-01-16
US20200087319A1 (en) 2020-03-19
MX2022010755A (es) 2022-09-23
CL2019003263A1 (es) 2020-04-17

Similar Documents

Publication Publication Date Title
TWI794232B (zh) 激酶抑制劑及其用途
TWI647214B (zh) 雙環稠合之雜芳基或芳基化合物類
TWI593683B (zh) 雙環稠合之雜芳基或芳基化合物
AU2016280137B2 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2016007185A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
CN117917410A (zh) pan-KRAS降解剂及其制备方法和应用
TW201506018A (zh) 二雜芳基化合物及其用途
WO2024125642A1 (zh) 含嘧啶多元并环类衍生物抑制剂、其制备方法和应用
TW201734020A (zh) 布魯頓氏酪胺酸激酶抑制劑及其使用方法
JP2021504380A (ja) Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
JP2023538091A (ja) Ｂｔｋ阻害剤としての複素環式化合物
WO2023109959A1 (zh) Cdk9抑制剂及其用途
WO2025232650A1 (zh) Kif18a抑制剂及其制备方法和用途
CN115557946A (zh) 杂环内酰胺类化合物，包含其的药物组合物及其用途
HK1245790B (en) Tricyclic compounds and their use as phosphodiesterase inhibitors